Trial Profile
A Phase 2, Two-part, Placebo-controlled, Parallel-group, Double-blind Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Participants 5 Years of Age and Older
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Fidrisertib (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FALKON
- Sponsors Blueprint Medicines; Clementia Pharmaceuticals
- 14 Jun 2022 Results from this study are expected to complete in August 2025, will enable evaluation of the efficacy and safety of IPN60130 in patients with FOP
- 14 Jun 2022 Trial design presented at the 104th Annual Meeting of the Endocrine Society.
- 03 May 2022 According to a Blueprint Medicines media release, the company Recognized a $30 million milestone payment from Clementia related to the initiation of this trial.